| Autor: |
A. Jalón Monzón, J. García Rodríguez, S. Escaf Bramada, J.M. Fernández Gómez, F.J. Regadera Sejas, M. Álvarez Múgica |
| Rok vydání: |
2008 |
| Předmět: |
|
| Zdroj: |
Actas Urológicas Españolas. 32:811-820 |
| ISSN: |
0210-4806 |
| DOI: |
10.1016/s0210-4806(08)73940-8 |
| Popis: |
INTRODUCTION Bladder cancer is a disease with a high prevalence due to its recurrence rate. Transurethral resection of the bladder (TURB) is the treatment in initial stages. Nevertheless, a high percentage of non-muscle-invasive tumors treated will have a recurrence 1-2 years afterwards. Adjuvant quemotherapy or immunotherapy after TURB has been administered in order to decrease the rate of recurrence and to prevent progression. PATIENTS AND METHODS A prospectived, controlled and randomized study was performed. We included 100 patients with non-muscle-invasive and bladder tumors the low grade. All patients had initially a TURB performed and were randomized to either receive or not a single dose mitomycin C (MMC) in the immediate postoperatory. RESULTS All low grade tumors was less than 3 cm. Mean follow-up was 26.43 +/- 7.65 months. MMC was administered in 49 patients, of these, 67.3% had no recurrence and 32.7% had a non-muscle-invasive recurrence. Of the 51 patients in the non mitomycin, 51% had no recurrence while 47% had a non-muscle-invasive recurrence, and 2% had a muscle-invasive progression. We found significantly differences in time to recurrence among the two groups. SUMMARY We found a greater time to recurrence in the group of single dose adjuvant MMC being this difference statistically significantly when comparing with the other group. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
